Clover Biopharmaceuticals Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG2280A1076
HKD
2.68
0.04 (1.52%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Golden Throat Holdings Group Co., Ltd.
Dawnrays Pharmaceutical Holdings Ltd.
TOT BIOPHARM International Co. Ltd.
Shanghai Henlius Biotech, Inc.
Charmacy Pharmaceutical Co., Ltd.
Hua Medicine Ltd.
Clover Biopharmaceuticals Ltd.
Transcenta Holding Ltd.
Abbisko Cayman Ltd.
Zhaoke Ophthalmology Ltd.
Fusen Pharmaceutical Co., Ltd.
Why is Clover Biopharmaceuticals Ltd. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Net Sales has grown by an annual rate of 653.92% and Operating profit at 30.73% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2
Flat results in Dec 24
  • CASH AND EQV(HY) Lowest at HKD 607.98 MM
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 857.14%, its profits have fallen by -849.6%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Clover Biopharmaceuticals Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Clover Biopharmaceuticals Ltd.
857.14%
5.09
113.74%
Hang Seng Hong Kong
27.36%
1.06
25.88%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
653.92%
EBIT Growth (5y)
30.73%
EBIT to Interest (avg)
-151.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.30
Sales to Capital Employed (avg)
-0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.64
EV to EBIT
-0.58
EV to EBITDA
-0.61
EV to Capital Employed
-0.27
EV to Sales
14.37
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Icon
Not enough Data to analyse Financial Trend
Icon
Not enough Data to analyse Financial Trend
Here's what is working for Clover Biopharmaceuticals Ltd.
Net Sales
Higher at HKD 52.63 MM
than preceding 12 month period ended Dec 2024
MOJO Watch
In the half year the company has already crossed sales of the previous twelve months

Net Sales (HKD MM)

Net Profit
Higher at HKD -899.73 MM
than preceding 12 month period ended Dec 2024
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (HKD MM)

Inventory Turnover Ratio
Highest at 0.16% and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio
Highest at 0.75%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -2,501% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Clover Biopharmaceuticals Ltd.
Cash and Eqv
Lowest at HKD 607.98 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents